Advenchen Pharmaceuticals, Llc.
Clinical trials sponsored by Advenchen Pharmaceuticals, Llc., explained in plain language.
-
Can a Dual-Target drug crack resistant gynecologic and breast cancers?
Disease control Not yet recruitingResearchers are testing an oral drug called AL58805, which blocks two cancer-growth proteins, PI3K and mTOR, in adults with advanced endometrial, cervical, soft tissue sarcoma, or breast cancers that have worsened after at least one standard treatment. Participants receive AL5880…
Phase 1/2 • Sponsor: Advenchen Pharmaceuticals, LLC. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can an oral drug that starves tumors help Hard-to-Treat cancers?
Disease control Not yet recruitingResearchers are testing an investigational oral drug called catequentinib hydrochloride (AL3818) in adults with advanced or metastatic endometrial cancer, low grade serous ovarian cancer, soft tissue sarcoma, or glioblastoma. The trial has two parts: a phase 1b part to find safe …
Phase 1/2 • Sponsor: Advenchen Pharmaceuticals, LLC. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC